Lumos Pharma Inc is a biotechnology company focused on developing innovative therapies for rare genetic diseases
The company specializes in creating treatments that target underlying biological mechanisms, aiming to improve patient outcomes through its proprietary drug development pipeline. Through a strong commitment to research and development, Lumos Pharma seeks to address unmet medical needs and enhance the quality of life for individuals affected by these rare conditions. Its dedicated team collaborates with healthcare professionals and advocates to advance its mission of providing effective and accessible treatments.
Lumos Pharma Inc (NASDAQLUMO) announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic (PK/PD) trial met all primary
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.
Gainers Opiant Pharmaceuticals, Inc. (NASDAQOPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus contingent value rights (CVRs) of up to $8.00 per share.
